{"id":58591,"date":"2023-12-15T16:01:20","date_gmt":"2023-12-15T15:01:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-cd3-antibodies-market-dosage-price-sales-report-2023-2028-5-billion-opportunity-clinical-trials-insights-on-250-antibodies-and-9-commercially-approved-cd3-antibodies-researchandmarke\/"},"modified":"2023-12-15T16:01:20","modified_gmt":"2023-12-15T15:01:20","slug":"global-cd3-antibodies-market-dosage-price-sales-report-2023-2028-5-billion-opportunity-clinical-trials-insights-on-250-antibodies-and-9-commercially-approved-cd3-antibodies-researchandmarke","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-cd3-antibodies-market-dosage-price-sales-report-2023-2028-5-billion-opportunity-clinical-trials-insights-on-250-antibodies-and-9-commercially-approved-cd3-antibodies-researchandmarke\/","title":{"rendered":"Global CD3 Antibodies Market, Dosage, Price, & Sales Report 2023-2028: $5 Billion Opportunity, Clinical Trials Insights on 250 Antibodies, and 9 Commercially Approved CD3 Antibodies – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a>
<\/a><\/p>\n

\nCD3 protein has emerged as a promising target that has significant therapeutic potential in various diseases. Over the years, several CD3 antibodies and anti-CD3 antibodies have been developed to assess the therapeutic effects of regulating the activity of CD3, which has led to the market entry of several CD3 antibodies and anti-CD3 antibodies that are performing well in their approved indications. The market for CD3 antibodies, though leans more towards cancer indications, is quite dynamic, with a lot of undiscovered potential, making it a domain to explore.<\/p>\n

\nThe first CD3 antibody to receive approval was Muromonab-CD3; this was followed by the approval of Removab (Catumaxomab). However, both these CD3 antibodies were withdrawn from the market for different clinical and commercial reasons, but, nevertheless, positioned themselves as pioneers of the CD3 antibodies market. Newer CD3 antibodies that entered the market after these had various modifications and were based on different technological platforms, which enabled them to avoid the same fate as their predecessors. As a result, there are nine antibodies, which have regulatory approvals from the FDA and EMA.<\/p>\n

\nAmong these nine, Blincyto (CD19 CD3) was the first to receive approval; it was approved in 2014 and entered the market in 2015, which allowed it to have a head start in the global CD3 antibodies market in terms of commercial performance. Sales of Blincyto have been increasing year because of its increasing uptake, which has been attributed to the drug being one of the most effective immunotherapies for acute lymphoblastic leukemia. Blincyto collected revenue of US$ 583 million in the year 2022, and in the first half of 2023, the drug has already generated a revenue of US$ 400 million, making it a dominating player in the global CD3 antibodies market.<\/p>\n

\nIt is also important to mention that the remaining eight CD3 antibodies were all approved in the years 2022 and 2023, and are only approved in limited regions, which has been disadvantageous for their sales and their share in the global CD3 antibodies market. All these were approved under the FDA’s accelerated approval program and the EMA’s conditional marketing approval program, and their continued approvals are awaited. Nevertheless, their developers are seeking approvals in other regions, which will help them generate more revenues in the market, potentially giving competition to Blincyto’s stance in the global market.<\/p>\n

\nIn terms of the clinical development of CD3 antibodies, different cancer indications are dominating. The approved CD3 antibodies have been approved to treat multiple myeloma, lymphoma, uveal melanoma and leukemia, and the same trend is being seen for CD3 antibody candidates in development. Moreover, a majority of these candidates are being developed as bispecific antibodies – T cell engagers to be precise – following a similar mechanism of action as Blincyto and other CD3 antibodies approved for use in cancer. Lindis Biotech, BioAtla, AstraZeneca, Regeneron, and Amgen are some pharmaceutical companies that have CD3 bispecific T cell engagers in development.<\/p>\n

\nBased on current commercial trends, the market for CD3 antibodies appears to be thriving, with various factors favorably influencing the market. Among these is the global market value of CD3 antibodies, which has been increasing every quarter as new antibodies are approved and introduced into the market.<\/p>\n

\nAnother factor is the involvement of important pharmaceutical corporations, which boosts the likelihood of success and financial returns associated with top CD3 antibodies. The invention and use of proprietary platforms, which enabled the development of unique CD3 T cell engagers, allowed developers to construct novel antibodies for rare indications, which came with regulatory benefits such as orphan drug designation. Overall, the global CD3 antibody market has enormous potential, much of which is yet relatively untapped.<\/p>\n

\nGlobal CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028 Report Highlights:<\/strong><\/p>\n